Life Technologies Buys Informatics Firm
Compendia Bioscience’s offerings include the cloud-based Oncomine software, which integrates cancer profiling data across cancer types for mining correlations among genetic signatures, clinical status and drug response markers; and OncoScore, which optimizes clinical trials by stratifying patients based on genetic signatures. Life Technologies plans to develop a clinical version of Oncomine and to add the Compendia workflow to its Ion Reporter semiconductor sequencing software.
Carlsbad, CA 10/8/12—Life Technologies has acquired cancer bioinformatics firm Compendia Bioscience for an undisclosed amount. Compendia Bioscience’s oncology data, including mutation profiles, gene expression data and cellular biomarkers, are used by pharmaceutical companies to identify new gene targets for drug discovery and development. “Compendia is highly regarded by its customers as a preeminent source of cancer biology expertise,” stated Ronnie Andrews, president of Medical Sciences at Life Technologies. “That expertise will serve as a content engine to drive development of diagnostic content across the breadth of Life platforms.” Life Technologies stated the acquisition also will enhance its companion diagnostics efforts, as it will now be able to offer products and services for target discovery and validation, biomarker analysis, clinical sample testing, companion diagnostics development and clinical implementation. Compendia Bioscience will retain its current management team. The acquisition is expected to be neutral to 2012 earnings and accretive to ROIC by 2015.
